Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock

Alkermes plc (NASDAQ:ALKS) EVP Craig Hopkinson sold 9,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $48.58, for a total transaction of $437,220.00. Following the completion of the sale, the executive vice president directly owned 69,389 shares in the company, valued at approximately $3,370,917.62. The trade was a 11.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alkermes Trading Up 0.3%

Shares of ALKS stock opened at $49.67 on Wednesday. Alkermes plc has a 12-month low of $25.17 and a 12-month high of $55.67. The company has a market capitalization of $8.33 billion, a P/E ratio of 130.71 and a beta of 0.34. The firm has a 50-day moving average price of $48.74 and a 200 day moving average price of $38.51. The company has a quick ratio of 1.85, a current ratio of 2.30 and a debt-to-equity ratio of 0.82.

Alkermes News Roundup

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Analysts maintain a generally favorable view of Alkermes, with the stock receiving a consensus rating of “Moderate Buy.” The broader analyst coverage includes several Buy or Overweight ratings, supporting investor confidence in the company’s outlook. Alkermes Receives Consensus Recommendation of Moderate Buy
• Neutral Sentiment: HC Wainwright issued an estimate for Alkermes’ third-quarter earnings, giving investors another reference point ahead of the results. The specific forecast was not provided, so the direct earnings implication remains unclear. HC Wainwright Estimates Alkermes’ Q3 Earnings
• Negative Sentiment: Director Nancy Lynn Md Snyderman sold 44,472 ALKS shares for approximately $2.24 million, reducing her direct ownership by about 74%. The unusually large reduction may weigh on sentiment, although insider selling does not necessarily indicate a deteriorating business outlook. SEC insider transaction filing
• Negative Sentiment: EVP Craig C. Hopkinson sold 9,000 shares valued at roughly $437,000, cutting his holdings by 11.48%. EVP David Joseph Gaffin also sold 2,034 shares for about $99,000, reducing his position by 0.89%. Both executive transactions were conducted under pre-arranged Rule 10b5-1 plans, which limits their value as discretionary bearish signals. Craig Hopkinson SEC insider transaction filing David Gaffin SEC insider transaction filing

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Cullen Frost Bankers Inc. acquired a new stake in shares of Alkermes during the 4th quarter worth approximately $28,000. Johnson Financial Group Inc. acquired a new position in Alkermes in the third quarter valued at approximately $31,000. UMB Bank n.a. boosted its stake in Alkermes by 57.6% in the fourth quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock valued at $34,000 after acquiring an additional 446 shares during the last quarter. Salomon & Ludwin LLC boosted its stake in Alkermes by 115.6% in the fourth quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company’s stock valued at $35,000 after acquiring an additional 667 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in Alkermes by 1,041.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,324 shares of the company’s stock worth $37,000 after acquiring an additional 1,208 shares during the period. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on ALKS shares. Royal Bank Of Canada lifted their price objective on Alkermes from $45.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, June 9th. Stifel Nicolaus restated a “buy” rating and set a $63.00 target price (up from $45.00) on shares of Alkermes in a report on Monday, July 20th. Zacks Research upgraded Alkermes from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. TD Cowen lifted their price target on Alkermes from $42.00 to $50.00 and gave the company a “buy” rating in a report on Monday, June 22nd. Finally, Weiss Ratings downgraded shares of Alkermes from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $54.56.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.